This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $193,752 to Boston Medical Center Corporation to implement and evaluate a video-coaching intervention called THRIVE to promote positive parenting behaviors among mothers with opioid use disorder (OUD). The goal is to test the effectiveness of this intervention in improving parenting and reducing child behavior problems for preschool-aged children, as well as...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) totaling $1,499,606.00 to the Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, with a project period from September 30, 2024 to July 31, 2029. The goal of this project is to characterize health outcomes from birth to 5 years of age in children born to individuals with opioid use disorder, identify disparities across populations,...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This federal Project Grant award, totaling $182,249, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund a study titled "Implementation of a Digitally Enhanced Intervention to Retain Pregnant and Postpartum People with Opioid Use Disorder in Buprenorphine Treatment" at the Medical University of South Carolina. The overall objective is to evaluate the feasibility and implementation of the...
The National Institute on Drug Abuse (NIDA) awarded a $326,410 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Berkshire Biomedical Corporation in Dallas, TX. The grant will fund a two-phased clinical study to evaluate the feasibility, acceptance, and impact on treatment retention of a hand-held, automated, personalized oral liquid dispensing system (COPA) for delivering take-home methadone to patients with opioid use disorder. The initial single-site pilot...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...